Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Objective. To characterize the symptom profile and time course in patients with Long COVID, along with the impact on daily life, work, and return to baseline health. Design. International web-based survey of suspected and confirmed COVID-19 cases with illness lasting over 28 days and onset prior to June 2020. Setting. Survey distribution via online COVID-19 support groups and social media Participants. 3,762 respondents from 56 countries completed the survey. 1166 (33.7%) were 40-49 years old, 937 (27.1%) were 50-59 years old, and 905 (26.1%) were 30-39 years old. 2961 (78.9%) were women, 718 (19.1%) were men, and 63 (1.7%) were nonbinary. 8.4% reported being hospitalized. 27% reported receiving a laboratory-confirmed diagnosis of COVID-19. 96% reported symptoms beyond 90 days. Results. Prevalence of 205 symptoms in 10 organ systems was estimated in this cohort, with 66 symptoms traced over seven months. Respondents experienced symptoms in an average of 9.08 (95% confidence interval 9.04 to 9.13) organ systems. The most frequent symptoms reported after month 6 were: fatigue (77.7%, 74.9% to 80.3%), post-exertional malaise (72.2%, 69.3% to 75.0%), and cognitive dysfunction (55.4%, 52.4% to 58.8%). These three symptoms were also the three most commonly reported overall. In those who recovered in less than 90 days, the average number of symptoms peaked at week 2 (11.4, 9.4 to 13.6), and in those who did not recover in 90 days, the average number of symptoms peaked at month 2 (17.2, 16.5 to 17.8). Respondents with symptoms over 6 months experienced an average of 13.8 (12.7 to 14.9) symptoms in month 7. 94.9% (94.1% to 95.6%) experienced relapses, with exercise, physical or mental activity, and stress as the main triggers. 86.7% (85.6% to 92.5%) of unrecovered respondents were experiencing fatigue at the time of survey, compared to 44.7% (38.5% to 50.5%) of recovered respondents. 45.2% (42.9% to 47.2%) reported requiring a reduced work schedule compared to pre-illness and 22.3% (20.5% to 24.3%) were not working at the time of survey due to their health conditions. Conclusions. Patients with Long COVID report prolonged multisystem involvement and significant disability. Most had not returned to previous levels of work by 6 months. Many patients are not recovered by 7 months, and continue to experience significant symptom burden.

[1]  A. Akrami,et al.  Patient-Led Research Collaborative: embedding patients in the Long COVID narrative , 2021, Pain reports.

[2]  W. Jo,et al.  A Two-Phase, Single Cohort Study of COVID-19 Antibody Sera-Surveillance , 2021, Annals of Epidemiology and Public Health.

[3]  Benjamin Bowe,et al.  High-dimensional characterization of post-acute sequelae of COVID-19 , 2021, Nature.

[4]  B. Kuehn Health Workers' Antibody Levels Wane After SARS-CoV-2 Infection. , 2021, JAMA.

[5]  P. Olliaro,et al.  Characterising long-term covid-19: a rapid living systematic review , 2020, medRxiv.

[6]  E. Sorbets,et al.  Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional study , 2020, Journal of Infection.

[7]  T. Greenhalgh,et al.  Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services , 2020, BMC Health Services Research.

[8]  P. Weihe,et al.  Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Putrino,et al.  Post-acute COVID-19 syndrome negatively impacts health and wellbeing despite less severe acute infection , 2020, medRxiv.

[10]  M. Nussenzweig,et al.  Evolution of Antibody Immunity to SARS-CoV-2 , 2020, bioRxiv.

[11]  Peter J Hellyer,et al.  Cognitive deficits in people who have recovered from COVID-19 , 2020, EClinicalMedicine.

[12]  David A. Drew,et al.  Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App , 2020, medRxiv.

[13]  F. Callard,et al.  How and why patients made Long Covid , 2020, Social Science & Medicine.

[14]  M. Spruit,et al.  Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? , 2020, ERJ Open Research.

[15]  A. Nath,et al.  Characterization of Post–exertional Malaise in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome , 2020, Frontiers in Neurology.

[16]  L. Weinstock,et al.  Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome , 2020, International Journal of Infectious Diseases.

[17]  M. Spruit,et al.  Care Dependency in Non-Hospitalized Patients with COVID-19 , 2020, Journal of clinical medicine.

[18]  N. Alwan Surveillance is underestimating the burden of the COVID-19 pandemic , 2020, The Lancet.

[19]  N. Maskell,et al.  Patient outcomes after hospitalisation with COVID-19 and implications for follow-up; results from a prospective UK cohort. , 2020, medRxiv.

[20]  T. Greenhalgh,et al.  Management of post-acute covid-19 in primary care , 2020, BMJ.

[21]  P. Schlagenhauf,et al.  Body temperature screening to identify SARS-CoV-2 infected young adult travellers is ineffective , 2020, Travel Medicine and Infectious Disease.

[22]  Jay S. Steingrub,et al.  Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[23]  Angelo Carfì,et al.  Persistent Symptoms in Patients After Acute COVID-19. , 2020, JAMA.

[24]  Wenjun Deng,et al.  Neurologic manifestations of nonhospitalized patients with COVID‐19 in Wuhan, China , 2020, MedComm.

[25]  Jeffrey J. Goldberger,et al.  COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors , 2020, Heart Rhythm.

[26]  P. Cameron,et al.  Temperature screening has negligible value for control of COVID‐19 , 2020, Emergency medicine Australasia : EMA.

[27]  Z. Tong,et al.  Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China , 2020, Emerging infectious diseases.

[28]  Y. Li,et al.  SARS-CoV-2 Detection in Different Respiratory Sites: A Systematic Review and Meta-Analysis , 2020, medRxiv.

[29]  L. Kucirka,et al.  Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure , 2020, Annals of Internal Medicine.

[30]  P. Whiting,et al.  Interpreting a covid-19 test result , 2020, BMJ.

[31]  N. Low,et al.  False-negative results of initial RT-PCR assays for COVID-19: A systematic review , 2020, medRxiv.

[32]  Joshua M Sharfstein,et al.  Diagnostic Testing for the Novel Coronavirus. , 2020, JAMA.

[33]  G. Bwire,et al.  Coronavirus disease-2019: is fever an adequate screening for the returning travelers? , 2020, Tropical Medicine and Health.

[34]  Qiuhan Zhang,et al.  Analytical comparisons of SARS-COV-2 detection by qRT-PCR and ddPCR with multiple primer/probe sets , 2020, Emerging microbes & infections.

[35]  B. Hatipoglu,et al.  Postural Orthostatic Tachycardia Syndrome and Its Unusual Presenting Complaints in Women: A Literature Minireview , 2018, Cureus.

[36]  Emily Jovic,et al.  Disability Accommodation in Nonstandard and Precarious Employment Arrangements , 2013 .

[37]  C. Shapiro,et al.  STOP, THAT and One Hundred Other Sleep Scales , 2012 .

[38]  Colin M. Shapiro,et al.  Fatigue Assessment Scale (FAS) , 2011 .

[39]  Ewan Klein,et al.  Natural Language Processing with Python , 2009 .

[40]  U. Graham,et al.  Postural orthostatic tachycardia syndrome , 2009, BMJ Case Reports.

[41]  V. Braun,et al.  Using thematic analysis in psychology , 2006 .

[42]  G. V. van Heck,et al.  Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). , 2004, British journal of health psychology.

[43]  Inderjit S. Dhillon,et al.  Concept Decompositions for Large Sparse Text Data Using Clustering , 2004, Machine Learning.

[44]  J. R. Scotti,et al.  Available From , 1973 .

[45]  D. Kleinbaum Survival Analysis: A Self-Learning Text , 1997 .

[46]  G. Pugliese,et al.  Severe Streptococcus pyogenes Infections, United Kingdom, 2003–2004 , 2008, Emerging infectious diseases.

[47]  B. Efron Better Bootstrap Confidence Intervals , 1987 .